Bioengineered chimpanzee adenovirus-based vaccines against tuberculosis: Optimization of immunologic property, formulation and delivery for bench-to-human applications

基于黑猩猩腺病毒的生物工程结核病疫苗：优化免疫特性、配方和交付以用于人体应用

• 批准号: 269861
• 负责人: Xing Zhou
• 金额: $ 35.46万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-10-01 至 2015-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=269861&lang=en
• 关键词: Aerosol Delivery; Bio-Formulation; Bioengieered Tuberculosis Vaccines; Chimpanzee Adenovirus Vector; Genetic Virus-Based Vectors; Human Adenovirus Vector; Human Health; Lung Tuberculosis; Mucosal Immunity; Mucosal Vaccination

Lung tuberculosis (TB) is one of the leading global infectious causes of death. TB still remains a serious health concern in Canada due to ever-increasing immigrant populations (latent TB), high incidence rates of TB in First Nations communities, and much

肺结核（TB）是全球主要的传染性死亡原因之一。结核病仍然是一个严重的健康问题， 加拿大由于不断增加的移民人口（潜伏性结核病），结核病在第一民族社区的高发病率，